Cancer medicines
Alpelisib
Alpelisib
A targeted therapy for selected PIK3CA-mutated breast cancers.
Sources checked · Introductory guide
On this page
How it works
It inhibits PI3K signaling to limit cancer cell growth.[3]
Where it is used
Used with fulvestrant after endocrine therapy in selected PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancers.[1]
Key safety points
Monitor for high glucose, severe rash and diarrhea. Plan glucose checks; report marked thirst, frequent urination, confusion or blistering rash immediately.[2]
Questions for your care team
- What are my PIK3CA result, glucose monitoring plan and contact thresholds?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Alpelisib (opens in a new tab)
- MedlinePlus · Alpelisib (opens in a new tab)
- NCI Drug Dictionary · Alpelisib (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.